Emergent BioSolutions Inc.
EBS · Price history
Price at last available close
$7.09
+$0.23 (+3.35%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Emergent BioSolutions Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox.
How they make money
Emergent BioSolutions operates as a life sciences company focused on addressing public health threats through a business model centered on government contracts and commercial product sales. The company generates revenue by developing, manufacturing, and supplying medical countermeasures for chemical, biological, radiological, nuclear, and explosive threats, as well as emerging infectious diseases, while also providing contract development and manufacturing services (CDMO) to third-party pharmaceutical partners.
Products & services
The company's portfolio includes NARCAN Nasal Spray and KLOXXADO for opioid overdose, as well as medical countermeasures for anthrax, smallpox, and other public health threats, alongside CDMO services.
Brands & revenue mix
Naloxone HCl nasal spray for opioid overdose reversal.
Separate brand revenue is not available in this research.Source
Naloxone HCl nasal spray for opioid overdose reversal.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Disclosed major customers
- U.S. Department of Health and Human Services (HHS) / BARDASource
Customer concentration
The company is highly dependent on the U.S. government, particularly HHS and BARDA, for a significant portion of its revenue through long-term procurement contracts.
Suppliers, materials & equipment
- Unnamed raw material and component suppliers — The company relies on various third-party suppliers for raw materials, components, and equipment necessary for the manufacturing of its medical countermeasures and CDMO services.Source
Strengths
- Established position as a primary supplier of medical countermeasures to the U.S. governmentSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
31
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
40
Weak
Financial Strength
58
Business Quality / Moat
28
Management
50
Growth Quality
29
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
34
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
43/100
Building Historical Record
Model Score 43/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for EBS
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can EBS maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is EBS's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is EBS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for EBS to reach sustainable profitability?
- •What future growth or profitability would be needed to justify EBS's current valuation?
Essential Investment Snapshot
Wall Street Score
31
Opportunity Score
34
Market Cap
$363.5M
P/E Ratio
-1.9
EPS
$-3.44
52-Week High
$14.06
52-Week Low
$4.36
Beta
2.34
Analyst Target
$10.00
Shares Outstanding
56.7M
Total Revenue
$770.2M
Total Debt
$581.8M
Dividend
No current dividend
Liquidation Value / Share
$6.02
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for EBS
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Debt service risk
Interest coverage is low (~1.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on EBS.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Established position as a primary supplier of medical countermeasures to the U.S. government.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −High dependency on U.S. government contracts and potential for funding fluctuations.
- −Strict regulatory oversight and compliance requirements associated with government contracting.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
31
Sep 21, 2026
Change
Unchanged
Current Score
31
Oct 1, 2026
Category Changes
EBS score was unchanged.
Projected Score
Projected Score
32
Projected Change
+0.4 points
Preliminary comparable-period financial changes suggest improvement of approximately 0.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$7.09
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $770.2M | $742.9M | $1.04B | $1.05B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $389.7M | $392.3M | $668.2M | $689.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $380.5M | $350.6M | $375.4M | $360.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $45.3M | $53.8M | $70.7M | $111.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $181.1M | $186.6M | $298.7M | $356.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $434.9M | $240.4M | $484.1M | $1.09B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$23.7M | $240.4M | $53.4M | -$47.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$54.4M | $110.2M | -$108.7M | -$726.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $50.9M | $59.3M | $71.0M | $87.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$146.0M | $82.8M | -$142.9M | -$731.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $30.8M | $30.2M | $47.7M | $29.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$176.8M | $52.6M | -$190.6M | -$760.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.44 | $0.98 | $-3.60 | $-14.85 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 51.60M | 53.50M | 53.00M | 51.20M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 51.60M | 56.70M | 53.00M | 51.20M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$234.3M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$3.49
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-13.9%
Cash Change
-48.5%
Margin Change
-68.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels. Pressure indicators included cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 66.3%. EPS increased 1486.4%. Cash declined 48.5%. Total debt declined 13.9%. Net income margin declined by 68.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Russian plague outbreak could boost these under-the-radar pharma stocks
Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares
Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)
Rumor Mill · EBS
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial